Scienture Holdings, Inc. (SCNX)
NASDAQ: SCNX · Real-Time Price · USD
0.9700
+0.0201 (2.12%)
At close: Apr 25, 2025, 4:00 PM
0.9690
-0.0010 (-0.10%)
After-hours: Apr 25, 2025, 6:40 PM EDT
Scienture Holdings Employees
As of December 31, 2024, Scienture Holdings had 19 total employees, including 14 full-time and 5 part-time employees. The number of employees did not change compared to the previous year.
Employees
19
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$7,192
Profits / Employee
$477,147
Market Cap
12.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 19 | 0 | - |
| Dec 31, 2023 | 19 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
SCNX News
- 5 days ago - SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025. - GlobeNewsWire
- 19 days ago - SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC. - GlobeNewsWire
- 24 days ago - Scienture Holdings, Inc. Issues Annual Letter to Shareholders - GlobeNewsWire
- 4 weeks ago - SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization - GlobeNewsWire
- 5 weeks ago - Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days - GlobeNewsWire
- 5 weeks ago - SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024. - GlobeNewsWire
- 7 weeks ago - SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P. - GlobeNewsWire
- 3 months ago - Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics - GlobeNewsWire